June 27, 2021 ~ TrialSite News ~ Andrew Bannister
All dangerous diseases are best treated early. A major failure of the global COVID-19 strategy has been to wait a week for the disease to become dangerous, when breathing becomes a problem. Early treatment of COVID, even for those with mild symptoms, prevents later hospitalization. There are several early treatment drugs showing promise but ivermectin leads the pack regarding safety, effectiveness and price. Unfortunately, the biggest players in Western mainstream media are members of the Trusted News Initiative (TNI). The TNI is a story for another day but it’s remarkable that big media companies barely report that they have agreed to promote global vaccination and to make sure any “disinformation myths are stopped in their tracks”[i]. Unfortunately, as a result early treatment seems to be seen as a disinformation myth and is not mentioned. Early treatment is vital in treating serious diseases and COVID-19 is no exception.
Considering the human and economic cost, the avoidance of early treatment with a very safe, effective and off-patent drug is a criminal tragedy of immense proportions and a winning lottery ticket for some pharmaceutical companies that are designing and selling novel patented drugs that could not compete with ivermectin in a free market. Mercks’ molnupiravir, for instance, is seeking an Emergency Use Authorization (EUA) from the FDA and “Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government.”[ii]
Ivermectin doesn’t need an EUA because it passed trials in 1986. It just needs to be recommended to treat COVID-19. However, if ivermectin was officially recognized as an effective treatment, it would legally prevent molnupiravir’s EUA until it passes trials and thus delay or endanger the $1.2 billion deal. An aggravating factor is the fact that molnupiravir (EIDD-2801) could cause harmful genetic mutations. [iii]
In the face of a public health crisis such as the COVID-19 pandemic, government authorities and international organizations have traditionally looked to the World Health Organization (WHO) for guidance – trusting that the WHO is free of commercial interests. Originally funded entirely by member states, the organization now receives less than 20% of its budget from these states and the rest from donors[iv] with their own financial and strategic agendas. Margret Chan, the previous Director General of the WHO, said in 2015: “I have to take my hat and go around the world to beg for money and when they give us the money [it is] highly linked to their preferences, what they like. It may not be the priority of the WHO, so if we do not solve this, we are not going to be as great as we were”. [v]